MEGA Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

MEGA Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of MEGA Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on MEGA Trial

CDC on MEGA Trial

MEGA Trial in the news

Blogs on MEGA Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for MEGA Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for MEGA Trial.

Objective

To assess whether evidence for treatment of hypercholesterolemia with statins derived from western populations can be extrapolated to the Japanese population.

Methods

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) was a prospective, randomized, open-labelled, blinded study which enrolled 8214 Japanese men and postmenopausal women aged 40 to 70 years and with a serum total cholesterol concentration of 220 to 270 mg/dL. All the patients were randomly assigned to receive either diet therapy alone or diet therapy plus pravastatin 10 to 20 mg daily and followed-up for a mean period of 5.3 years.

Results

The following results were obtained at the end of follow-up period:

  • Mean total cholesterol was reduced by 2.1% and 11.5% in the patients treated with diet alone and diet plus pravastatin respectively.
  • Similarly mean LDL-C reduced by 3.2% and 18.0%.
  • Significantly lower CAD in patients treated with diet plus pravastatin than in those treated with diet alone.

Conclusion

Treatment with a low dose of pravastatin reduces the risk of CAD in Japan by much the same amount as higher doses have shown in Europe and the USA.[1][2]

References

  1. Nakamura H, Arakawa K, Itakura H; et al. (2006). "Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial". Lancet. 368 (9542): 1155–63. doi:10.1016/S0140-6736(06)69472-5. PMID 17011942. Unknown parameter |month= ignored (help)
  2. Nakamura H (2009). "[Primary prevention trial by lowering hyperlipidemia on the cardiovascular disease (MEGA Study)]". Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics (in Japanese). 46 (1): 18–21. PMID 19246826. Unknown parameter |month= ignored (help)